Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUSP3 | P51452 | 6/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.56 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.52 |
| ▸ | SMURF2 | Q9HAU4 | 1/20 | 0.49 |
| ▸ | SMURF1 | Q9HCE7 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.43 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.43 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5590836 | 0.85 | IP6K1 (0.58) | DUSP3PTPN1PIN1SMURF2SMURF1 | |
| SCHEMBL4076415 | 0.83 | PTPN1 (0.67) | DUSP3PTPN1PIN1SMURF2SMURF1 | |
| SCHEMBL1545025 | 0.83 | L3MBTL1 (0.53) | TRPV1L3MBTL1 | |
| SCHEMBL2490559 | 0.82 | DUSP3 (0.53) | DUSP3PTPN1PIN1TRPV1NPC1 | |
| SCHEMBL1686250 | 0.82 | ALOX5 (0.53) | DUSP3PTPN1SMURF2SMURF1TRPV1 | |
| SCHEMBL1227041 | 0.80 | DUSP3 (0.56) | DUSP3PTPN1PIN1TRPV1NPC1 | |
| SCHEMBL17261679 | 0.77 | SMURF1 (0.69) | DUSP3PTPN1SMURF2SMURF1TRPV1 | |
| SCHEMBL1166739 | 0.77 | PIN1 (0.56) | DUSP3PTPN1PIN1NPC1RAB9A | |
| SCHEMBL1544648 | 0.75 | PTGS1 (0.43) | TRPV1NPC1RAB9APTGS1PTGS2 | |
| SCHEMBL5591183 | 0.75 | IP6K1 (0.52) | DUSP3PTPN1SMURF2SMURF1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399451-B2 | Heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-19 | — | — | US | disclosed |
| US-20110190255-A1 | HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-04 | — | — | US | disclosed |
| US-7585881-B2 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2009-09-08 | — | — | US | disclosed |
| US-20080045571-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
| US-20080015204-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
| US-20080015234-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
| US-20070293545-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-12-20 | — | — | US | disclosed |
| US-20070179188-A1 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-08-02 | — | — | US | disclosed |
| US-20050272779-A1 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015234-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | GRM5, GRIK5, GRM2 | DUSP3 2461/4885PTPN1 1658/4885PIN1 2780/4885 |
| US-20070179188-A1 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM5, GRIK5, GRM2 | DUSP3 2507/4885PTPN1 1563/4885PIN1 2725/4885 |
| US-20050272779-A1 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM5, GRIK5, GRM2 | DUSP3 2461/4885PTPN1 1658/4885PIN1 2780/4885 |
| US-20110190255-A1 | HETEROCYCLIC COMPOUNDS | S1PR1, S1PR3, S1PR5 | DUSP3 2904/4885PTPN1 698/4885PIN1 4861/4885 |
| US-20080045571-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | GRM5, GRIK5, GRM2 | DUSP3 2461/4885PTPN1 1658/4885PIN1 2780/4885 |
| US-20070293545-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | GRM5, GRIK5, GRM2 | DUSP3 2461/4885PTPN1 1658/4885PIN1 2780/4885 |
| US-20080015204-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | GRM5, GRIK5, GRM2 | DUSP3 2461/4885PTPN1 1658/4885PIN1 2780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.